Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline

NCT06653153 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06653153
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06653153 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 24, 2024
Completion date
October 31, 2030
Enrollment
1,400 (estimated)
Sites
262

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease